Skip to main content
. 2011 Oct 28;157(3):269–274. doi: 10.1159/000328784

Table 1.

Percentages (with numbers in parentheses) of subjects with a doubling in antibody from day 0 to day 47 in each treatment group

Anti-KLH antibody 50-μg SS (n = 5) 250-μg SS (n = 10) 100-μg ID (n = 4) 250-μg ID (n = 5)
IgA 40 (2) 50 (5) 75 (3) 100 (5)
IgG 60 (4) 50 (5) 100 (4) 100 (5)
IgM 0 (0) 50 (5) 50 (2) 80 (4)
IgG1 60 (3) 40 (4) 75 (3) 80 (4)
IgG2 60 (3) 40 (4) 67 (2 of 3) 80 (4)
IgG3 80 (4) 60 (6) 75 (3) 80 (4)